格隆汇3月27日丨华领医药-B(02552.HK)公布,2024年标志着公司华堂宁®在中国内地被纳入国家医保药品目录的首个完整年度。因此,2024财政年度的销售收入较2023年同期增加234%至人民币255.9百万元。于2024财政年度,华堂宁®的销售遍布中国内地约2,700家医院。截至2024年12月31日,华领医药的资产负债表保持稳健,现金结余达人民币1,139.8百万元,以支持其全面商业化、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.